Actively Recruiting
Optimal Timing for Staged Complete Revascularization in STEMI Patients With Multivessel Disease Using Fractional Flow Reserve Guidance The OPTION-STEMI2 Trial
Led by Chonnam National University Hospital · Updated on 2026-10-23
1252
Participants Needed
30
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the best timing for staged complete revascularization using fractional flow reserve FFR in patients with ST-segment elevation myocardial infarction STEMI and multivessel coronary artery disease. This prospective, multicenter, open-label trial aims to compare in-hospital staged PCI of non-infarct related artery non-IRA lesions versus out-of-hospital staged PCI to determine which approach better reduces adverse cardiac events. The study addresses a gap in knowledge about optimal treatment timing following successful primary PCI of the infarct-related artery IRA.
CONDITIONS
Brief Title
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
Research Team
M
Min Chul Kim, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here